← FDA DRUG APPROVALS

FDA ANDA · ANDA204439

TIGECYCLINE

Sponsor: APOTEX

APPLICATION
ANDA204439
TYPE
ANDA
ORIGINAL APPROVAL
2018-12-21
LATEST ACTION
2025-08-06
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

TIGECYCLINEPrescription
TIGECYCLINE 50MG/VIAL · POWDER · INTRAVENOUS

Approval history

2025-08-06Labeling · Supplement 7 · standardAP
2021-02-01Labeling · Supplement 3 · standardAP
2018-12-21UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →